Market overview
The global federated learning drug discovery market is worth USD 104 mn in 2026 and is forecast to reach USD 642 mn by 2036, growing at a 20.0% CAGR. United States is the largest country market and Software platforms is the largest by offering segment.
| Scope | Software platforms and managed collaborations that let pharma and biotech train drug discovery models on partners' data without sharing the data itself: federated learning, secure data collaboration and related consulting. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 85 mn |
| Value 2026 | USD 104 mn |
| Value 2036 | USD 642 mn |
| CAGR 2026-2036 | 20.0% |
| Volume 2026 | 634 platform deployments |
| Volume 2036 | 3,928 platform deployments |
| Average price 2026 | USD 163,500 per platform deployment |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Federated Learning Drug Discovery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 104 mn |
| 2027 | USD 124 mn |
| 2028 | USD 149 mn |
| 2029 | USD 179 mn |
| 2030 | USD 215 mn |
| 2031 | USD 258 mn |
| 2032 | USD 310 mn |
| 2033 | USD 372 mn |
| 2034 | USD 446 mn |
| 2035 | USD 535 mn |
| 2036 | USD 642 mn |
Federated Learning Drug Discovery market segmentation
By offering
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Software platforms | 48.0% | 52.3% | USD 50 mn | 21.0% |
| Managed collaborations | 32.0% | 32.1% | USD 33 mn | 20.0% |
| Consulting and integration | 20.0% | 15.6% | USD 21 mn | 17.0% |
By user
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Large pharma consortia | 52.0% | 43.3% | USD 54 mn | 17.8% |
| Biotechnology companies | 28.0% | 35.3% | USD 29 mn | 22.8% |
| Academic and contract research | 20.0% | 21.4% | USD 21 mn | 20.8% |
By deployment
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cloud | 60.0% | 68.0% | USD 62 mn | 21.5% |
| Hybrid | 22.0% | 20.0% | USD 23 mn | 18.9% |
| On-premises | 18.0% | 12.0% | USD 19 mn | 15.2% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Target identification | 20.0% | 19.0% | USD 21 mn | 19.4% |
| Molecular property prediction | 30.0% | 28.0% | USD 31 mn | 19.2% |
| Toxicity and ADMET | 20.0% | 22.0% | USD 21 mn | 21.1% |
| Clinical trial optimisation | 15.0% | 17.0% | USD 16 mn | 21.5% |
| Biomarker discovery | 15.0% | 14.0% | USD 16 mn | 19.2% |
By data type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Chemical and compound data | 34.0% | 32.0% | USD 35 mn | 19.3% |
| Genomic and omics | 30.0% | 32.0% | USD 31 mn | 20.8% |
| Imaging | 18.0% | 18.0% | USD 19 mn | 20.0% |
| Clinical and health records | 18.0% | 18.0% | USD 19 mn | 20.0% |
Top 25 countries for federated learning drug discovery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 91.0% of 2026 revenue and the 25 countries below together hold 97.9%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 44 mn | 42.0% | USD 275 mn | 20.2% |
| 2 | United Kingdom | USD 11 mn | 11.0% | USD 69 mn | 19.8% |
| 3 | Germany | USD 8.3 mn | 8.0% | USD 48 mn | 19.2% |
| 4 | France | USD 7.3 mn | 7.0% | USD 42 mn | 19.3% |
| 5 | Switzerland | USD 6.2 mn | 6.0% | USD 38 mn | 19.8% |
| 6 | China | USD 5.2 mn | 5.0% | USD 39 mn | 22.2% |
| 7 | Japan | USD 4.2 mn | 4.0% | USD 23 mn | 18.7% |
| 8 | Netherlands | USD 3.1 mn | 3.0% | USD 19 mn | 19.6% |
| 9 | Canada | USD 3.1 mn | 3.0% | USD 19 mn | 19.6% |
| 10 | Denmark | USD 2.1 mn | 2.0% | USD 12 mn | 19.4% |
| 11 | India | USD 0.82 mn | 0.8% | USD 7.2 mn | 24.3% |
| 12 | South Korea | USD 0.72 mn | 0.7% | USD 4.2 mn | 19.3% |
| 13 | Singapore | USD 0.61 mn | 0.6% | USD 4.5 mn | 22.1% |
| 14 | Sweden | USD 0.61 mn | 0.6% | USD 3.6 mn | 19.4% |
| 15 | Belgium | USD 0.52 mn | 0.5% | USD 3.0 mn | 19.3% |
| 16 | Israel | USD 0.52 mn | 0.5% | USD 3.0 mn | 19.3% |
| 17 | Australia | USD 0.52 mn | 0.5% | USD 3.0 mn | 19.3% |
| 18 | Spain | USD 0.41 mn | 0.4% | USD 2.4 mn | 19.1% |
| 19 | Italy | USD 0.41 mn | 0.4% | USD 2.4 mn | 19.1% |
| 20 | Ireland | USD 0.41 mn | 0.4% | USD 2.4 mn | 19.1% |
| 21 | Finland | USD 0.31 mn | 0.3% | USD 1.8 mn | 19.2% |
| 22 | Norway | USD 0.31 mn | 0.3% | USD 1.8 mn | 19.2% |
| 23 | Austria | USD 0.31 mn | 0.3% | USD 1.8 mn | 19.2% |
| 24 | United Arab Emirates | USD 0.31 mn | 0.3% | USD 2.2 mn | 21.9% |
| 25 | Brazil | USD 0.31 mn | 0.3% | USD 2.2 mn | 21.9% |
| Rest of world | USD 2.2 mn | 2.1% | USD 13 mn | 19.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- NVIDIA
- Owkin
- Apheris
- Eli Lilly
- IBM
Group 2: Regional and specialist players
- Rhino Health
- Lifebit
- Duality Technologies
- Flower Labs
- Bitfount
Group 3: Emerging and niche players
- Sherpa.ai
- Devron
- TensorOpera
- Enveil
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the federated learning drug discovery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 20.0% is calculated from the resulting values.
The market is divided by offering, by user, by deployment, by application, by data type. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the federated learning drug discovery market?
The global federated learning drug discovery market is estimated at USD 85 mn in 2025 and USD 104 mn in 2026.
How fast will the federated learning drug discovery market grow?
It is forecast to reach USD 642 mn by 2036, a compound annual growth rate of 20.0% from 2026, an increase of USD 538 mn.
Which country is the largest market for federated learning drug discovery?
United States is the largest market by revenue at USD 44 mn in 2026, 42.0% of the global total. The three largest countries together hold 61.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 22.2% a year from 2026 to 2036.
Which federated learning drug discovery segment is largest?
In the by offering split, Software platforms is the largest segment with 48.0% of 2026 revenue.
Who are the leading federated learning drug discovery companies?
Global leaders include NVIDIA, Owkin, Apheris, Eli Lilly.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Breast Cancer Grading ToolsUSD 102 mn · 17.0% CAGR
- Isokinetic Diagnostic and Training SystemUSD 110 mn · 5.5% CAGR
- Brachytherapy Treatment Planning SystemsUSD 95 mn · 5.8% CAGR
- Ostomy Irrigation ProductsUSD 94 mn · 4.3% CAGR
- Bioabsorbable StentsUSD 92 mn · 7.0% CAGR
- Medical Telepresence RobotsUSD 119 mn · 8.0% CAGR
- Aquaculture Fungal Infection TreatmentUSD 90 mn · 6.0% CAGR
- Impedance-based TEER Measurement SystemUSD 120 mn · 9.0% CAGR